Key result
Homozygous CryAB R120G mutation fails to induce overt cardiomyopathy in mice through 12 months.
Why the study?
To better understand pathogenic mechanisms underlying human CryAB R120G-associated cardiomyopathy, appropriate in vivo models are essential.
Does the homozygous CryAB R120G knock-in mutation induce cardiomyopathy in mice?
Does the homozygous CryAB R120G knock-in mutation induce cardiomyopathy in mice?
The CryAB R120G knock-in mouse model does not recapitulate the overt cardiomyopathy seen in human patients with this mutation within the first year of life.
Answers are grounded in this paper and cite their sources.
Questions CryAB R120G knock-in model fidelity for human disease; leaves open need for extended follow-up or modifiers.
Alpha B-crystallin (CryAB) is a small heat-shock protein highly expressed in cardiac tissue, where it functions as a molecular chaperone that helps prevent protein aggregation, particularly under stress conditions. A missense mutation in CryAB (R120G) causes autosomal dominant cardiomyopathy in humans and is characterized by extensive protein aggregation in cardiomyocytes. To better understand the pathogenic mechanisms underlying CryAB R120G -associated cardiomyopathy, appropriate in vivo models are essential. Genetic mouse models are valuable tools for investigating disease pathogenesis and evaluating potential therapeutic strategies. In this study, we characterized a homozygous CryAB R120G knock-in (KI) mouse model to assess the impact of this mutation on cardiac function. CryAB R120G KI mice exhibited no overt changes in cardiac structure and function up to 12 months of age, with minimal changes in cardiac and proteotoxic stress markers, except for an increased atrial natriuretic peptide expression at 12 months. Protein quality control pathways remained largely unchanged. Although mitochondrial respiration was normal in young CryAB R120G KI mice, it was reduced at 12 months of age. Despite the presence of insoluble protein aggregates, homozygous CryAB R120G KI mice did not develop overt structural or functional cardiomyopathy through 12 months of age. These findings indicate that, within the age range examined, the CryAB R120G KI model does not reproduce the overt cardiomyopathic phenotype associated with the CRYAB R120G mutation in patients.
No takes yet. Share an insight, caveat, or question.
Quiles et al. (2026) studied Cardiomyopathy. CryAB R120G knock-in mutation vs. Wild-type mice was evaluated on Cardiac structure and function. The homozygous CryAB R120G knock-in mutation did not induce overt structural or functional cardiomyopathy in mice through 12 months of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: